Lizza Hendriks
@HendriksLizza
Followers
1K
Following
1K
Media
1
Statuses
425
Pulmonologist - thoracic oncology, esp brain metastases @MaastrichtUMC @GROW_UM- member @DeJongeAkademie - @myESMO #LungCancer faculty - @EORTC - Views my own
Maastricht, Nederland
Joined March 2019
RT @sitcancer: Manage NSCLC in the perioperative, metastatic, & second-line setting with insights from leading experts! Join us Sept. 12 fo….
0
3
0
RT @JordiRemon: In NSCLC & AGA we usually use the ⬆️ dose of targeted therapies despite no always correlation btw dose and efficacy or intr….
0
17
0
RT @myESMO: 📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents n….
0
15
0
RT @OncNewsCentral: #ASCO25: Final results from #CheckMate816 confirm OS benefit—nivolumab + chemo cuts risk of death by 28% in resectable….
oncologynewscentral.com
New CheckMate 816 data show that adding nivolumab to neoadjuvant chemotherapy for NSCLC reduced the risk for death by nearly 30% compared with chemotherapy alone.
0
1
0
RT @myESMO: 📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options appr….
0
17
0
RT @OncNewsCentral: #ASCO25: Final results from #CheckMate816 confirm OS benefit—nivolumab + chemo cuts risk of death by 28% in resectable….
oncologynewscentral.com
New CheckMate 816 data show that adding nivolumab to neoadjuvant chemotherapy for NSCLC reduced the risk for death by nearly 30% compared with chemotherapy alone.
0
1
0
RT @JessicaMenis: EORTC Lung Group present at ASCO 2025! Excellent oral abstract discussions of Chair @JordiRemon and Secretary @HendriksLi….
0
9
0
RT @DrJNaidoo: #ASCO25 Lung orals🔥. Accomplished discussion by @HendriksLizza of CM816, NeoADAURA & Deluge LC screening/IPN study. Key next….
0
1
0
RT @HHorinouchi: ☑️#ASCO25 🆙.☑️#LCSM Oral, LocReg/SCLC.🔥DISCUSSION: The Earlier the Better? From Detection to Treatment of Localized Lung C….
0
7
0
RT @g_mountzios: Α big lung cancer family comes together every year and @ASCO united by a common passion and vision and of course by our un….
0
10
0
The Electronic Ballot Vote to elect the ESMO Directors and Nomination Committee Chair and members is now open! @myESMO members opportunity to vote for my wonderful lung colleagues @MartinReck2 @NReguart @DrSanjayPopat ! #LCSM.
0
0
13
RT @etop_ibcsg: Out now in @LungCaJournal: Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial:….
0
5
0
RT @triparnasen: Thank you so much @g_mountzios for the kind words! Your support truly means a lot. I am honored to be among such an incred….
0
1
0
RT @g_mountzios: Elections for members of the @IASLC board are open with many excellent candidates from all over the 🌍🌎🌏.including those am….
0
8
0
Very happy to share that I have been nominated for @IASLC board of directors! Contributing to fostering, mentoring and teaching the new generation of colleagues combined with moving the field of thoracic oncology forward is my passion. Please vote
lnkd.in
This link will take you to a page that’s not on LinkedIn
1
8
53
RT @g_mountzios: #ELCC25 saves the best for last!! Day 4 with two cutting-edge sessions focusing on #IO resistance and next generation #ADC….
0
3
0
RT @DrJNaidoo: #ELCC25 ADCs in NSCLC . Superb overview by @HendriksLizza identifying gaps in our knowledge:.- ideal pt population .- biomar….
0
20
0
RT @myESMO: 📣Updated: ESMO Guidelines Slideset: Oncogene-Addicted Metastatic Non-small Cell Lung Cancer v1.2. 👉 Find Clinical Practice Guid….
0
24
0
RT @myESMO: 📣Join us for the upcoming #ESMOGuidelines Webinar! .Dive deep into EGFR-mutated #mNSCLC, resistance mechanisms, and cutting-edg….
0
7
0